The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND ...

Atea Pharmaceuticals is actively engaging with investors by hosting a live conference call and audio webcast to report financial results and provide a business update. The company is focused on the ...

Shares of the mid-cap biopharma Atea Pharmaceutical (NASDAQ: AVIR) are up by a respectable 21.5% as of 11:44 a.m. EDT Friday morning. The biotech's shares are taking flight today in response to a ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Atea Pharmaceuticals (AVIR) announced that new data will be presented supporting the combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor and ruzasvir, an NS5A inhibitor, as ...

Shares of Ulta Beauty were down 5% Tuesday morning. The company is holding its annual investor conference today, and prior to the beginning of its presentation, it released long-term financial targets ...

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ...

Atea Pharmaceuticals is developing the oral drug, AT-527, in partnership with Roche and both the companies are collaborating on multiple studies of the drug for the treatment of Covid-19. n the ...

An announcement from Atea ASA ( (ATAZF)) is now available. Atea ASA has continued its previously announced share buyback program, which runs from August 18, 2025, to April 30, 2026, with authorization ...